Hardman & Co Research Report

Hardman & Co issues research report on Tissue Regenix Group plc

From development - into the commercial world: Tissue Regenix is no longer an R&D play. Its dCELL® technology allows for the production of 'like-for-like' tissue specific, structure-preserving scaffolds that have been validated in multiple clinical settings. Following the US launch of DermaPure®, we expect a series of further product launches over the next two years in Orthopaedic Sports Medicine and heart valve replacement, substantial markets with significant unmet medical need. The Company continues to build long term value despite short term monthly cashburn of ~£0.8m. An NPV of 42p is driven by three core product areas; the true value of the platform and product streams has still to be elucidated.

Please click here for the full report:

http://www.hardmanandco.com/system/files/research_papers/TRX%20Initiation%20Note%20-%2025%20January%202016.pdf

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.